University announces launch of Aviation Impact Accelerator (AIA) – a team of experts in aerospace, economics, policy, and climate science, who are building an interactive simulator to help achieve net zero flight.
The city’s West Cambridge site will be transformed into a dynamic Innovation District, connecting world-class researchers with world-class businesses, creating thousands of jobs and providing a ‘sense of place’ and amenities for residents.
Connect: Health Tech, the University of Cambridge Enterprise Zone, has today launched a roadmap, ‘Creating a University Enterprise Zone for Cambridge across the life and physical sciences’, that examines the challenges faced in futureproofing and sustaining the growth of the life sciences cluster to maintain Cambridge as a global centre of excellence for health tech.
Formula 1 is to fund an undergraduate student from an underrepresented background to study for an engineering degree at the University of Cambridge. The scholarship will be administered by the Cambridge Trust and will cover tuition fees and maintenance costs for the four year duration of the course.
The Trinity Challenge has announced the winners of its inaugural competition, and is investing a £5.7 million (US$8 million) charitable pledged prize fund into one grand prize winner, two 2nd prize winners, and five 3rd prize winners.
Pioneering collaboration initiated by the University of Cambridge, Imperial College London and University College London
The problem with being a futurist, says Richard Watson, is that change is happening a lot faster and a lot crazier these days. We talk to him about his recent work with the Entrepreneurship Centre and why thinking about a ‘preferred’ future is a good thing.
Researchers have created a plant-based, sustainable, scalable material that could replace single-use plastics in many consumer products.
The so-called ‘bullshit jobs theory’ – which argues that a large and rapidly increasing number of workers are undertaking jobs that they themselves recognise as being useless and of no social value – contains several major flaws, argue researchers from the universities of Cambridge and Birmingham.
Three companies, Astex Pharmaceuticals, Eisai Ltd and Eli Lilly and Company, are joining forces with research scientists across Cambridge to explore promising new approaches to the treatment of neurodegenerative disease.
© 2025 University of Cambridge